Methods for cascade amplifications of therapeutic payloads (CATP) & compositions for cancer immunotherapies and gene therapy
A nucleic acid construct composition with sa-mRNA and virus structural proteins delivered via LNPs addresses the specificity and delivery challenges of existing cancer treatments, achieving targeted cancer cell death and enhanced immune response.
Patent Information
- Application Number
- PCT/US2025/019051
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-24
- Filing Date
- 2025-03-07
- Publication Date
- 2025-11-06
AI Technical Summary
Current cancer treatments, including viral vectors, chemotherapy, and surgery, lack specificity to target cancerous cells while preserving normal cells, risking off-target effects and face challenges in manufacturing and delivery of therapeutic agents like mRNA, leading to immune responses and reduced efficacy.
A composition comprising a first nucleic acid construct encoding self-amplifying mRNA (sa-mRNA) and a second nucleic acid construct encoding virus structural proteins, delivered via a non-viral payload system, specifically an LNP, to enhance gene expression and viral particle production in cancer cells.
The composition induces targeted cancer cell death, increases gene expression by up to 500-fold, and enhances central memory CD8 T cell count, demonstrating improved cancer treatment efficacy with reduced off-target effects.